Dexcom shares are trading higher ahead of the company's presentation at the Wells Fargo Healthcare Conference. UBS maintained a Buy rating on the stock but cut its price target.
Portfolio Pulse from Benzinga Newsdesk
Dexcom's shares are trading higher in anticipation of the company's presentation at the Wells Fargo Healthcare Conference. UBS has maintained a Buy rating on the stock but has reduced its price target.
September 06, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dexcom's stock is trading higher due to the upcoming presentation at the Wells Fargo Healthcare Conference. Despite UBS lowering its price target, it maintains a Buy rating on the stock.
The anticipation of Dexcom's presentation at the Wells Fargo Healthcare Conference has led to an increase in the company's stock price. UBS's decision to maintain a Buy rating, despite lowering the price target, indicates continued confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100